相关实验视频

Updated: Jul 8, 2026

Preparation and Evaluation of 99mTc-labeled Tridentate Chelates for Pre-targeting Using Bioorthogonal Chemistry

Preparation and Evaluation of ^99mTc-labeled Tridentate Chelates for Pre-targeting Using Bioorthogonal Chemistry

Published on: February 4, 2017

开发具有Niraparib HYNIC衍生物的Tc标记综合体,用于PARP阳性瘤成像

Qianna Wang¹, Junhong Feng^1,2, Yuhao Jiang^1,3

¹Key Laboratory of Radiopharmaceuticals of the Ministry of Education, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), College of Chemistry, Beijing Normal University, Beijing 100875, P. R. China.

Molecular pharmaceutics

|January 8, 2025

概括

研究人员开发了一种新的标有 technetium-99m 的成像剂,用于针对癌症治疗的聚基 (ADP-ribose) 聚合酶-1 (PARP-1). 该药物[99mTc]Tc-(TPPTS/tricine) -NPBHYNIC在临床前研究中显示出有前途的瘤吸收和特异性.

科学领域:

核医学是一种核医学.
放射化学放射化学是指辐射化学.
在瘤学瘤学.

背景情况:

聚ADP-ribose) 聚合酶-1 (PARP-1) 是DNA修复中的关键酶,也是癌症治疗的治疗标.
用放射性标记抑制剂进行核医学成像可以评估PARP-1表达的治疗选择.

研究的目的:

开发和评估一种基于niraparib的新型技术-99m ([99mTc]) 标记成像剂,用于向瘤中的PARP-1.

主要方法:

尼拉帕里布被修改,以创建HYNIC结合的配体NPBHYNIC.
NPBHYNIC被放射性标记为[99mTc]Tc和各种合体.
复杂稳定性,生物分布和瘤向特异性在体外和体内使用小鼠模型进行了评估.

主要成果:

[99mTc]Tc标记的复合物在体外是水友和稳定的.
[99mTc]Tc-(TPPTS/tricine) -NPBHYNIC与[99mTc]Tc-(NIC/tricine) -NPBHYNIC (0.36 ± 0.05% ID/g) 相比,已经证明了较高的瘤吸收 (1.02 ± 0.07% ID/g).
生物分布和SPECT/CT成像证实了[99mTc]Tc-(TPPTS/tricine) -NPBHYNIC的PARP-1特异性.

结论:

[99mTc]Tc-(TPPTS/tricine) -NPBHYNIC是一种有前途的PARP-1特异性瘤成像剂.
这种药物有可能根据PARP-1表达水平指导癌症治疗选择.

关键词:

阴尼主义者阴尼主义者在PARP中,PARP是PARP.在TPPTS中,我们可以使用TPPTS.尼拉帕里布里布里布.技术-99m是一种

更多相关视频

Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models

Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models

Published on: March 13, 2018

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Automated Preparation of [⁶⁸Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

相关概念视频